- Home
- IPSC vs ATNM Comparison
IPSC vs ATNM Comparison
Compare IPSC & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- ATNM
- Stock Information
- Founded
- IPSC 2019
- ATNM 2000
- Country
- IPSC United States
- ATNM United States
- Employees
- IPSC N/A
- ATNM N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- ATNM Health Care
- Exchange
- IPSC Nasdaq
- ATNM Nasdaq
- Market Cap
- IPSC 48.2M
- ATNM 51.5M
- IPO Year
- IPSC 2021
- ATNM N/A
- Fundamental
- Price
- IPSC $0.53
- ATNM $1.54
- Analyst Decision
- IPSC Strong Buy
- ATNM Strong Buy
- Analyst Count
- IPSC 5
- ATNM 3
- Target Price
- IPSC $3.33
- ATNM $4.67
- AVG Volume (30 Days)
- IPSC 719.1K
- ATNM 229.8K
- Earning Date
- IPSC 05-15-2025
- ATNM 05-09-2025
- Dividend Yield
- IPSC N/A
- ATNM N/A
- EPS Growth
- IPSC N/A
- ATNM N/A
- EPS
- IPSC N/A
- ATNM N/A
- Revenue
- IPSC $114,898,000.00
- ATNM N/A
- Revenue This Year
- IPSC $833.10
- ATNM N/A
- Revenue Next Year
- IPSC N/A
- ATNM N/A
- P/E Ratio
- IPSC N/A
- ATNM N/A
- Revenue Growth
- IPSC 8286.72
- ATNM N/A
- 52 Week Low
- IPSC $0.34
- ATNM $1.03
- 52 Week High
- IPSC $3.46
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- IPSC 46.73
- ATNM 49.81
- Support Level
- IPSC $0.48
- ATNM $1.56
- Resistance Level
- IPSC $0.59
- ATNM $1.69
- Average True Range (ATR)
- IPSC 0.04
- ATNM 0.11
- MACD
- IPSC -0.00
- ATNM -0.01
- Stochastic Oscillator
- IPSC 34.62
- ATNM 32.18
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.